

# TABLE OF CONTENTS

<b>Cardiology Care I</b> .....	1	Anticancer Agents Associated with Development of HF .....	88
Cardiology Care I Panel .....	3	Anticancer Therapies Associated with AF .....	97
<b>Updates in the Management of Heart Failure</b>		Anticancer Therapies Associated with QTc Prolongation .....	98
<i>By Harleen Singh, Pharm.D., BCPS, BCACP</i>		Anticancer Agents Associated with the Development of Myocarditis .....	98
Introduction .....	7	Conclusion .....	103
Recently Approved Treatments for Patients with HF .....	9	References .....	104
Clinical Guidelines in Drug Therapy Management .....	13	Self-Assessment Questions .....	107
Patient-Centered Approach for Optimizing GDMT .....	17		
Conclusion .....	22	<b>Cardiology Care III</b> .....	111
References .....	23	Cardiology Care III Panel .....	113
Self-Assessment Questions .....	26		
<b>Dyslipidemia Management Updates</b>		<b>Stable Ischemic Heart Disease Management Updates</b>	
<i>By Bruce A. Warden, Pharm.D., FNLA, FASPC, BCPS, CLS</i>		<i>By Emily K. McCoy, Pharm.D., FCCP, BCACP</i>	
Introduction .....	31	Introduction .....	117
Clinical Guideline Updates in Drug Therapy Management .....	33	Clinical Presentation .....	118
New Agents Approved for Management of Dyslipidemia .....	38	Guideline-Directed Medical Therapy for SIHD .....	119
Updates in Management of Statin Intolerance .....	45	Antithrombotic Therapy in SIHD .....	124
Promising Pharmacotherapies in the Pipeline .....	48	Colchicine Use in SIHD .....	134
Conclusion .....	51	Conclusion .....	134
References .....	51	References .....	135
Self-Assessment Questions .....	54	Self-Assessment Questions .....	138
<b>Cardiology Care II</b> .....	57	<b>Pharmacogenomics and Cardiovascular Disease</b>	
Cardiology Care II Panel .....	59	<i>By Dyson T. Wake, Pharm.D., BCPS; and James C. Lee, Pharm.D., FCCP, BCACP, AACC</i>	
<b>DOAC Use in Special Populations</b>		Introduction .....	143
<i>By Jeffery L. Kibert II, Pharm.D., BCPS; Arthur L. Allen, Pharm.D., CACP; and Bishoy Ragheb, Pharm.D., BCACP, CACP</i>		Interpreting PGx Results .....	148
Introduction .....	63	PGx of P2Y12 Inhibitors .....	151
DOACs in Patients with Obesity .....	63	PGx of Vitamin K Antagonists .....	153
DOACs in Patients with Renal Dysfunction .....	65	PGx of Statins .....	156
DOACs in Patients with Hepatic Dysfunction .....	66	PGx Associations with Growing Evidence .....	157
DOACs in Patients with Valvular Heart Disease .....	67	Conclusion .....	161
Hypercoagulable Conditions .....	69	References .....	161
DOACs in Patients with COVID-19 .....	71	Self-Assessment Questions .....	164
References .....	73		
Self-Assessment Questions .....	76	<b>Cardiology Care IV</b> .....	169
<b>Updates in Cardio-Oncology</b>		Cardiology Care IV Panel .....	171
<i>By Sandra Cuellar, Pharm.D., FHOPA, FASHP, BCOP; and Erika L. Hellenbart, Pharm.D., BCPS</i>		<b>Interactive Case: Role of Colchicine in Secondary Prevention of CVD</b>	
Introduction .....	81	<i>By Augustus (Rob) Hough, Pharm.D., BCPS, BCCP</i>	
Anticancer Therapies Associated with Vascular Toxicity .....	82	Interactive Case: Role of Colchicine in Secondary Prevention of CVD .....	175

References .....	176
Self-Assessment Questions .....	177

### **Interactive Case: Lower Extremity Peripheral Artery Disease**

*By Kristin Watson, Pharm.D., BCCP*

Interactive Case: Lower Extremity Peripheral Artery Disease .....	182
References .....	182
Self-Assessment Questions .....	185

### **Interactive Case: Telehealth and Self-Monitoring of Blood Pressure**

*By Courtney Doyle-Campbell, Pharm.D., MBA, BCACP, AHSCP-CHC*

Interactive Case: Telehealth and Self-Monitoring of Blood Pressure .....	189
References .....	190
Self-Assessment Questions .....	192